Skip to main content
Log in

Selection of microRNA for providing tumor specificity of transgene expression in cancer gene therapy

  • Molecular Cell Biology
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract

The use of tumor-specific microRNA loss to inhibit transgene expression in normal cells is considered as a way to increase the specificity of gene-therapeutic antitumor drugs. This method assumes the introduction of recognition sites of suppressed in tumor cells microRNAs into transgene transcipt. In the presented work, the efficiency of the strategy for providing the tumor specificity of transgene expression depending on parameters of microRNA expression in normal and tumor cells was studied. It was established that microRNA suppression in tumor cells and the determination of absolute microRNA levels in tumor and normal cells are not sufficient for the adequate estimation of the possibility of specific microRNA usage in the scheme of cancer gene therapy, and particularly do not allow to exclude a significant decrease in the efficiency of the gene-therapeutic drug upon the introduction of microRNA recognition sites. These parameters are only suitable for the preliminary selection of microRNA. The effect of introduction of microRNA recognition sites on transgene expression level in target tumor cells should be validated experimentally. It is suggested that this should be done directly in the cancer gene therapy scheme with monitoring of the therapeutic transgene activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

3'-UTR:

3'-untranslated region

5FC:

5-fluorocytosine

CD:UPRT:

yeast hybrid protein cytosine deaminase: uracil-phosphoribosyltransferase

References

  1. Dorer D.E., Nettelbeck D.M. 2009. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug Deliv. Rev. 61, 554–571.

    Article  CAS  PubMed  Google Scholar 

  2. Shepelev M.V., Korobko E.V., Georgiev G.P., Sverdlov E.D., Korobko I.V. 2011. Application of mRNA regulatory regions to improve tumor specificity of transgene expression. Cancer Gene Ther. 18, 682–684.

    Article  CAS  PubMed  Google Scholar 

  3. Korobko I.V. 2014. MicroRNAs in cancer gene therapy: Another look. Curr. Cancer Ther. Rev. 10, 271–276.

    Article  CAS  Google Scholar 

  4. Jin H., Lv S., Yang J., Wang X., Hu H., Su C., Zhou C., Li J., Huang Y., Li L., Liu X., Wu M., Qian Q. 2011. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS ONE. 6, e21307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kuzmin D.V., Vinogradova T.V., Kopantzev E.P., Sverdlov E.D. 2010. Cre-LoxP mediated strong enhancement of pBIRC5 promoter driven suicide of cancer cells with CD/UPRT and fluorocytosine. Open Gene Ther. J. 3, 31–39.

    CAS  Google Scholar 

  6. Masotti A., Caputo V., Da Sacco L., Pizzuti A., Dallapiccola B., Bottazzo G.F. 2009. Quantification of small non-coding RNAs allows an accurate comparison of miRNA expression profiles. J. Biomed. Biotechnol. 2009, 659028.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Doench J.G., Petersen C.P., Sharp P.A. 2003. siRNAs can function as miRNAs. Genes Dev. 17, 438–442.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Xia X.M., Jin W.Y., Shi R.Z., Zhang Y.F., Chen J. 2010. Clinical significance and the correlation of expression between Let-7 and K-ras in non-small cell lung cancer. Oncol. Lett. 1, 1045–1047.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Jay C., Nemunaitis J., Chen P., Fulgham P., Tong A.W. 2007. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 26, 293–300.

    Article  CAS  PubMed  Google Scholar 

  10. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T., Takahashi T. 2004. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64, 3753–3756.

    Article  CAS  PubMed  Google Scholar 

  11. Tang Y., Liu D., Zhang L., Ingvarsson S., Chen H. 2011. Quantitative analysis of miRNA expression in seven human foetal and adult organs. PLoS ONE. 6, e28730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sen R., Ghosal S., Das S., Balti S., Chakrabarti J. 2014. Competing endogenous RNA: The key to posttranscriptional regulation. Sci. World J. 2014, 896206.

    Article  Google Scholar 

  13. Detzer A., Engel C., Wünsche W., Sczakiel G. 2011. Cell stress is related to re-localization of Argonaute 2 and to decreased RNA interference in human cells. Nucleic Acids Res. 39, 2727–3741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. V. Shepelev.

Additional information

Original Russian Text © M.V. Shepelev, S.V. Kalinichenko, P.N. Vikhreva, I.V. Korobko, 2016, published in Molekulyarnaya Biologiya, 2016, Vol. 50, No. 2, pp. 327–335.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shepelev, M.V., Kalinichenko, S.V., Vikhreva, P.N. et al. Selection of microRNA for providing tumor specificity of transgene expression in cancer gene therapy. Mol Biol 50, 284–291 (2016). https://doi.org/10.1134/S0026893316020229

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893316020229

Keywords

Navigation